The estimated Net Worth of Thomas J Spoerel is at least $928 Тысяча dollars as of 10 June 2024. Mr. Spoerel owns over 300 units of Becton Dickinson & Co stock worth over $461,771 and over the last 5 years he sold BDX stock worth over $466,695. In addition, he makes $0 as Chief Accounting Officer, Principal Accounting Officer, Vice President и Controller at Becton Dickinson & Co.
Sign up
Mr. Spoerel BDX stock SEC Form 4 insiders trading
Thomas has made over 7 trades of the Becton Dickinson & Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 300 units of BDX stock worth $71,793 on 10 June 2024.
The largest trade he's ever made was exercising 1,026 units of Becton Dickinson & Co stock on 7 June 2022 worth over $151,520. On average, Thomas trades about 144 units every 82 days since 2019. As of 10 June 2024 he still owns at least 1,976 units of Becton Dickinson & Co stock.
You can see the complete history of Mr. Spoerel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Spoerel biography
Thomas J. Spoerel is Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller of the Company. Mr. Spoerel joined BD in September 2015 as Vice President Finance and Deputy Controller, and became Vice President Finance and Controller in December 2018. Prior to joining BD, Mr. Spoerel served as Vice President Finance and Corporate Controller of Catalent, Inc.
How old is Thomas Spoerel?
Thomas Spoerel is 41, he's been the Chief Accounting Officer, Principal Accounting Officer, Vice President и Controller of Becton Dickinson & Co since 2019. There are 34 older and no younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.
What's Thomas Spoerel's mailing address?
Thomas's mailing address filed with the SEC is C/O BECTON, DICKINSON AND COMPANY, , FRANKLIN LAKES, NJ, 07417.
Insiders trading at Becton Dickinson & Co
Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown и Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.
What does Becton Dickinson & Co do?
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
What does Becton Dickinson & Co's logo look like?
Complete history of Mr. Spoerel stock trades at Becton Dickinson & Co
Becton Dickinson & Co executives and stock owners
Becton Dickinson & Co executives and other stock owners filed with the SEC include:
-
Vincent Forlenza,
Executive Chairman of the Board -
Patrick Kaltenbach,
Executive Vice President, President - Life Sciences -
Thomas Polen,
President, Chief Executive Officer, Chief Operating Officer, Director -
Christopher Reidy,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer -
Alberto Mas,
Executive Vice President, President - Medical Segment -
Thomas E. Polen Jr.,
Pres, CEO & Chairman -
Samrat Khichi,
Executive Vice President - Public Policy and Regulatory Affairs -
Alexandre Conroy,
Executive Vice President, Chief Integrated Supply Chain Officer -
Vincent A. Forlenza,
Exec. Chairman -
Samrat S. Khichi,
Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel -
Alberto Mas,
Exec. VP & Pres of the Medical Segment -
Samrat S. Khichi Esq.,
Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel -
Christopher R. Reidy,
Exec. VP, CFO & Chief Admin. Officer -
Simon D. Campion,
Exec. VP & Pres of Interventional Segment -
Christopher DelOrefice,
Exec. VP & CFO -
Marshall Larsen,
Lead Independent Director -
Bertram Scott,
Independent Director -
Claire Fraser,
Independent Director -
Christopher Jones,
Independent Director -
Catherine Burzik,
Independent Director -
Claire Pomeroy,
Independent Director -
Timothy Ring,
Independent Director -
Rebecca Rimel,
Independent Director -
David Melcher,
Independent Director -
Jeffrey Henderson,
Independent Director -
R. Andrew Eckert,
Independent Director -
John DeFord,
Executive Vice President, Chief Technology Officer -
James Lim,
Executive Vice President, President, Greater Asia -
Thomas Spoerel,
Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller -
Monique Dolecki,
Investor Relations Contact Officer -
Charles Bodner,
Senior Vice President, Corporate Finance -
Roland Goette,
Executive Vice President, President - EMEA -
Simon Campion,
Executive Vice President and President, BD Interventional Segment -
Betty Larson,
Executive Vice President- Human Resources, Chief Human Resources -
Denise Fleming,
Exec. VP of Technology & Global Services and Chief Information Officer -
Francesca M. DeMartino,
Sr. VP of Investor Relations -
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.,
Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board -
Troy Kirkpatrick,
VP of PR -
Elizabeth McCombs,
Exec. VP & Chief Technology Officer -
Michelle Quinn,
Sr. VP and Chief Ethics & Compliance Officer -
Jerry Flasz,
Exec. VP of Global Services & Chief Information Officer -
Dr. John A. DeFord,
Exec. VP of R&D and CTO -
Thomas J. Spoerel,
Sr. VP, Controller & Chief Accounting Officer -
Joanne Waldstreicher,
Director -
Gary A Mecklenburg,
Director -
John E Gallagher,
VP, Corp Finance and Treasurer -
Linda M Tharby,
Segment Pres. Life Sciences -
Wilard J Jr Overlock,
Director -
Nabil Shabshab,
Senior Vice President -
Jeffrey S Sherman,
VP and General Counsel -
Basil Anderson,
Director -
Ellen R Strahlman,
Senior Vice President -
James F Orr,
Director -
William A Tozzi,
VP and Controller -
Gary M Cohen,
President - BD Medical Systems -
Stephen Sichak,
Senior Vice President -
Henry P Jr Becton,
Director -
Carrie L Byington,
Director -
Edward Degraan,
Director -
William A Kozy,
Pres - BD CLS and Cmpy Oper -
Alfred Sommer,
Director -
David Shan,
EVP and Chief ISC Officer -
Shana Carol Neal,
EVP and Chief People Officer -
John P Groetelaars,
EVP -
James W Borzi,
EVP & Chief Supply Chain Offcr -
Suketu Upadhyay,
Senior VP and Controller -
Adel Mahmoud,
Director -
Jerome V Hurwitz,
Senior Vice President -
Donna M Boles,
Sr. Exec VP - Human Resources -
David V Elkins,
Executive VP and CFO -
David T Durack,
Senior Vice President -
William E. Rhodes,
Senior Vice President -
Joseph Mercurio,
VP and Corporate Controller -
Patricia B Shrader,
Senior Vice President -
Scott P Bruder,
SrVP; Chief Technology Officer -
Cathy E. Minehan,
Director -
Margeretha Af Ugglas,
Director -
Edward J Ludwig,
Chairman, President and CEO -
James E Perrella,
Director -
Alfred John Hanson,
Executive Vice President -
John R Considine,
Executive VP and CFO -
Jean Marc Dageville,
VP - Human Resources -
Harry N Beaty,
Director -
Frank Albert Olson,
Director -
Bridget M Healy,
VP, Gen Counsel and Secy -
Christopher Del Orefice,
EVP & Chief Financial Officer -
Antoine C Ezell,
EVP, President NA & CMO -
David Hickey,
EVP & President, Life Sciences -
William M Brown,
Director -
Rishi Grover,
EVP and Chief ISC Officer -
Michael David Garrison,
EVP & President Medical -
Richard Byrd,
EVP & President Interventional -
Pavan Kumar Mocherla,
EVP & President Greater Asia -
Michael Feld,
EVP & President, Life Sciences